Payment overview · 2025
General Payments
$174.04
13 reported records · 2 companies
Healthcare provider profile · identity verified
Ryan Michael Lee
Allopathic & Osteopathic Physicians|Internal Medicine · METAIRIE, LA · NPI 1659695161
Verified facts
What the public records show
CMS Open Payments records show Ryan Michael Lee received $174.04 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 92.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.05 | 92.0% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.99 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.04 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $160.05 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $160.05 | 12 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 852 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 796 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 607 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 570 | 157 |
| Losartan Potassium | Losartan Potassium | 456 | 138 |
| Valsartan | Valsartan | 418 | 138 |
| Hydrochlorothiazide | Hydrochlorothiazide | 338 | 109 |
| Gabapentin | Gabapentin | 317 | 110 |
| Omeprazole | Omeprazole | 304 | 100 |
| Irbesartan | Irbesartan | 291 | 77 |
| Metformin Hcl | Metformin Hcl | 290 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 251 | 119 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 82 |
| Furosemide | Furosemide | 234 | 80 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 229 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 68 |
| Trazodone Hcl | Trazodone Hcl | 195 | 50 |
| Carvedilol | Carvedilol | 191 | 60 |
| Bupropion Xl | Bupropion Hcl | 177 | 53 |
| Ozempic | Semaglutide | 175 | 32 |
| Alendronate Sodium | Alendronate Sodium | 174 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 36 |
| Ezetimibe | Ezetimibe | 122 | 39 |
| Finasteride | Finasteride | 120 | 37 |
| Mounjaro | Tirzepatide | 120 | 21 |
| Potassium Chloride | Potassium Chloride | 118 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 26 |
| Eliquis | Apixaban | 117 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 115 | 23 |
| Allopurinol | Allopurinol | 113 | 33 |
| Buspirone Hcl | Buspirone Hcl | 110 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 28 |
| Azelastine Hcl | Azelastine Hcl | 108 | 65 |
| Celecoxib | Celecoxib | 100 | 31 |
| Pregabalin | Pregabalin | 97 | 26 |
| Alprazolam | Alprazolam | 96 | 22 |
| Jardiance | Empagliflozin | 96 | 25 |
| Sertraline Hcl | Sertraline Hcl | 94 | 29 |
| Methocarbamol | Methocarbamol | 90 | 39 |
| Lisinopril | Lisinopril | 89 | 34 |
| Metformin Hcl Er | Metformin Hcl | 89 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 24 |
| Glipizide Er | Glipizide | 87 | 32 |
| Januvia | Sitagliptin Phosphate | 85 | 19 |
| Meloxicam | Meloxicam | 84 | 42 |
| Montelukast Sodium | Montelukast Sodium | 82 | 27 |
| Telmisartan | Telmisartan | 82 | 25 |
| Atenolol | Atenolol | 81 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 27 |
| Simvastatin | Simvastatin | 78 | 24 |
| Tramadol Hcl | Tramadol Hcl | 71 | 22 |
| Chlorthalidone | Chlorthalidone | 68 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 67 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 14 |
| Colchicine | Colchicine | 58 | 23 |
| Fenofibrate | Fenofibrate | 58 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 16 |
| Glipizide | Glipizide | 53 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 14 |
| Ondansetron Odt | Ondansetron | 49 | 26 |
| Nifedipine Er | Nifedipine | 47 | 16 |
| Propranolol Hcl | Propranolol Hcl | 47 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 44 |
| Temazepam | Temazepam | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 15 |
| Lorazepam | Lorazepam | 44 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 16 |
| Naproxen | Naproxen | 41 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 16 |
| Spironolactone | Spironolactone | 41 | 18 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 14 |
| Memantine Hcl | Memantine Hcl | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 39 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 15 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Famotidine | Famotidine | 29 | 11 |
| Ketoconazole | Ketoconazole | 29 | 17 |
| Lidocaine | Lidocaine | 28 | 17 |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 11 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | 11 |
| Sumatriptan | Sumatriptan | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.04 · 13 records | Novo Nordisk Inc | Ozempic, Rybelsus, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error